B-51 did not show a statistically significant recurrence benefit from regional irradiation in its selected post-chemotherapy ypN0 population. The confidence interval and surgery-specific comparison remain important.
Randomised comparison in biopsy-proven cT1 to T3 N1 M0 breast cancer that became pathologically node-negative after neoadjuvant chemotherapy. The 2025 report enrolled 1,641 patients; 1,556 entered the primary-event analysis, 772 with irradiation and 784 without. The primary endpoint counted invasive breast cancer recurrence or death from breast cancer.
The radiation contrast depended on surgery: after lumpectomy, both groups received whole-breast radiation with or without nodal fields; after mastectomy, chest-wall plus nodal irradiation was compared with none. A study-level statement about omission must retain these different strategies.
Informs the specified response-adapted radiation question with uncertainty. Residual-node-positive trials and personal treatment decisions require their own population and protocol context.
Shares Systemic versus local therapy, Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Systemic versus local therapy, Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Systemic versus local therapy and the tags education-audit, local-treatment.
Shares IMRT / IGRT (modern external beam), Breast cancer (all types) and the tags education-audit, local-treatment.
Shares NSABP B-51 / RTOG 1304, Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/